Phase 2 Seliciclib Trial for Cushing Disease Marked Completed

A clinical trial update for corticotropin-related research was recorded on October 16, 2026. The trial, titled "Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease," is registered as NCT03774446. It is a Phase 2 study and its status has been updated to completed. Cushing disease involves overproduction related to corticotropin activity, and this trial examined seliciclib, also known as R-roscovitine, in that context. The registry entry reflects the study's current status as completed, meaning the trial has concluded its planned activities. No results, outcomes, or efficacy data are included in this status update. The record does not specify whether findings have been posted or published separately. Readers interested in the specific data from this study should consult the official registry entry for further detail, as this brief reports only the status change itself. This update is based solely on the trial registry information available as of the stated date. For broader context on corticotropin as a compound, including its regulatory status and general background, readers can refer to the compound overview.